This is a mechanism module, not a specific disease. Do NOT create a "Beta-Adrenergic Receptor Blockade" Disease entry. Disorder entries reference individual nodes via conforms_to, for example "beta_adrenergic_receptor_blockade#Reduced cAMP-Dependent Protein Kinase Activity".
Scope. The module opens at the drug-receptor interaction and stops at the organism-level haemodynamic outcome. What produced the sympathetic drive being antagonised (neurohormonal activation in heart failure, a catecholamine surge, thyrotoxicosis) belongs to the conforming entry, as does the disease-specific consequence of lowering that drive. The intracellular calcium-handling chain is deliberately absent: a conformer that needs it should also conform to `cardiac_camp_pka_calcium_handling`, whose nodes carry it.
Selectivity is a precondition, not a decoration. The airway arm is reachable only by agents that occupy ADRB2. A conforming entry that declares the airway arm should name the agent and its selectivity; the cited pharmacovigilance review found no asthma deaths attributable to cardioselective beta-1 blockers, so a class-wide bronchospasm claim is not supported.
Ontology bindings. GO has no bronchoconstriction class (searched OLS for "bronchoconstriction" and "bronchus smooth muscle contraction", which return CHEBI and CL hits only), so the airway node is bound to GO:0044557 relaxation of smooth muscle with modifier DECREASED, which states the loss of relaxant tone rather than asserting a contraction term that does not exist. No CHEBI binding appears on any node, per the create-module convention that module nodes bind GO and CL terms only; the beta-blockers themselves are bound as `therapeutic_agent` on the treatments.
The ocular arm is deliberately absent. Topical timolol lowers intraocular pressure and would look like a fourth tissue arm, but whether that action runs through ciliary-epithelial cAMP is disputed - PMID:11502564 argues for a cAMP-independent effect on the ciliary epithelium - so adding it would assert a funnelling through this module's central effector that the literature does not settle. Glaucoma is therefore not offered as a conformer here.
Migraine is absent for a different reason. Beta-blockers are established migraine prophylaxis, but how they prevent attacks is not settled, and no step of this module has been shown to be the one that does it, so conforming a migraine entry here would assert a mechanism rather than record one. The same applies to the other uses of non-selective blockade named on that treatment (portal hypertension, thyrotoxicosis): the drug is the same, the mechanism reaching the clinical benefit is not this module's to claim.
Beta-Adrenergic Receptor Antagonist Occupancy
trigger
A beta-adrenergic receptor antagonist occupies the orthosteric site of ADRB1 (and, for non-selective agents, ADRB2), competitively excluding norepinephrine and epinephrine. Occupancy is competitive and therefore graded: the fraction of receptors silenced depends on the antagonist concentration set against the prevailing catecholamine drive, which is why the same dose has a larger effect under sympathetic activation than at rest. The node is the drug action itself, not a lesion.
Used by disorders
Heart Failure
as Beta-Adrenergic Receptor Blockade (Beta-Blocker Target)
Downstream
-
Loss of Gs Coupling and Adenylyl Cyclase Activation
Receptor occupancy without agonist-induced conformational change leaves the receptor unable to engage Gs.
Show evidence (2 references)
"Beta-adrenoceptor antagonists competitively inhibit the binding of endogenous catecholamines to beta1-adrenoceptors in the heart."
States the competitive-occupancy mechanism this node describes, and names the receptor subtype the cardiac arm depends on.
"β1 adrenoreceptors predominate in the heart, activate the Gs-adenylyl cyclase -cAMP-protein kinase A signaling cascade, and induce positive inotropic and chronotropic effects"
Names the receptor subtype the antagonist displaces agonist from, and what that receptor does when agonist-occupied. Quoted for receptor identity; the consequences of blocking it are the inference the downstream nodes carry.
Loss of Gs Coupling and Adenylyl Cyclase Activation
amplifier
An antagonist-occupied beta-adrenergic receptor does not adopt the active conformation, so it does not catalyse nucleotide exchange on Gs-alpha and does not stimulate adenylyl cyclase. Basal and agonist-driven cAMP production both fall, the latter much more than the former. This is the step at which receptor-level pharmacology becomes a second-messenger change, and it is where the module's tissue arms diverge: the same loss of Gs coupling plays out differently in cardiomyocytes, juxtaglomerular granular cells and airway smooth muscle.
Downstream
-
Reduced cAMP-Dependent Protein Kinase Activity
Less cAMP leaves the PKA regulatory subunits bound, so fewer catalytic subunits are released.
Show evidence (2 references)
"By signaling Gs, a cAMP-dependent pathway is initiated through adenylyl cyclase"
Names the coupling step the antagonist denies the receptor. StatPearls is cited here for textbook receptor pharmacology only, not as a primary source.
"Mice with selective Gs-alpha (Gsα) deficiency in juxtaglomerular granular cells show a marked reduction of basal renin secretion, and an almost complete unresponsiveness of renin release to furosemide, hydralazine, or isoproterenol."
Genetic removal of Gs-alpha from a cell type this module reaches abolishes both basal output and the response to a beta-agonist, which is the consequence this node asserts for pharmacological loss of Gs coupling.
Reduced cAMP-Dependent Protein Kinase Activity
central effector
Falling cAMP leaves protein kinase A holoenzyme intact, reducing the pool of free catalytic subunit and so the phosphorylation of its targets. This is the module's key conformance target: every therapeutic and adverse arm below funnels through it, and a conforming disorder entry substitutes the PKA substrate that matters in its tissue rather than re-deriving the receptor chain. It is also the point of contact with `cardiac_camp_pka_calcium_handling`, which carries the opposite direction of travel.
Downstream
-
Reduced Sinoatrial and Atrioventricular Nodal Firing
Less PKA-dependent phosphorylation of the cardiac pacemaker and conduction apparatus.
-
Reduced Myocardial Contractility
Less PKA-dependent phosphorylation of the contractile and calcium-handling apparatus.
-
Reduced Juxtaglomerular Renin Release
Renin exocytosis from granular cells is cAMP/PKA-dependent.
-
Loss of Beta-2-Mediated Bronchiolar Smooth Muscle Relaxation
In airway smooth muscle the same cAMP/PKA fall removes a relaxant tone rather than a stimulatory one. Reached only by agents that occupy ADRB2.
Show evidence (1 reference)
"Physiological stimulation of renin secretion and expression relies on the activation of regulatory pathways that converge on the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway."
Supports treating cAMP/PKA as the convergence point several upstream stimuli share, which is what makes it the module's conformance target rather than one arm among many.
Reduced Sinoatrial and Atrioventricular Nodal Firing
effector
Loss of PKA-dependent phosphorylation slows diastolic depolarization in sinoatrial pacemaker cells and slows conduction through the atrioventricular node: negative chronotropy, and the rate-control effect in atrial fibrillation. It is also the dose-limiting effect (bradycardia, heart block) - one mechanism read two ways depending on the patient.
Downstream
-
Reduced Myocardial Workload and Oxygen Consumption
A slower ventricular rate lowers oxygen consumption per minute.
Show evidence (1 reference)
"Targeted activation of the beta-1 receptor in the heart increases sinoatrial (SA) nodal, atrioventricular (AV) nodal, and ventricular muscular firing, thus increasing heart rate and contractility."
Names the three cardiac sites and the two functions this node reports as reduced. Stated for receptor activation; blockade is the inference.
Reduced Myocardial Contractility
effector
Loss of PKA-dependent phosphorylation of the contractile and calcium-handling apparatus reduces the force and the rate of relaxation of working cardiomyocytes: negative inotropy. In heart failure this is the acute cost that up-titration is designed to get past, which is why it is a separate node from the nodal effect rather than bundled with it.
Downstream
-
Reduced Myocardial Workload and Oxygen Consumption
A less forcefully contracting ventricle consumes less oxygen per beat.
Show evidence (1 reference)
"Targeted activation of the beta-1 receptor in the heart increases sinoatrial (SA) nodal, atrioventricular (AV) nodal, and ventricular muscular firing, thus increasing heart rate and contractility."
Names the three cardiac sites and the two functions this node reports as reduced. Stated for receptor activation; blockade is the inference.
Reduced Juxtaglomerular Renin Release
effector
Renin exocytosis from juxtaglomerular granular cells is cAMP/PKA-dependent and carries a beta-adrenergic component, so beta-blockade lowers plasma renin activity and with it angiotensin II generation and aldosterone release. This is the renal arm of the antihypertensive effect and is mechanistically separate from the cardiac arm, which is why a conforming entry may declare one without the other.
Downstream
-
Reduced Myocardial Workload and Oxygen Consumption
Lower angiotensin II and aldosterone reduce afterload and volume, lowering cardiac work.
Show evidence (2 references)
"In addition, β-adrenergic receptors are critical for the expression of high basal levels of renin and for its release response to lowering blood pressure or MD sodium chloride concentration."
Establishes that renin expression and release depend on beta-adrenergic input, which is the input this module removes.
"In the kidney, smooth muscle cells in the juxtaglomerular apparatus contract and release renin."
Locates the renin-releasing cell population this node names. Stated for receptor activation; blockade is the inference.
Reduced Myocardial Workload and Oxygen Consumption
consequence
The organism-level outcome the therapeutic indications share: a heart doing less work per minute, at a lower blood pressure, with a smaller oxygen requirement at rest and under exertion. In angina this raises the ischaemic threshold; in hypertension it lowers blood pressure; in heart failure with reduced ejection fraction the benefit is the chronic withdrawal of sympathetic drive rather than the acute haemodynamic change, which is why initiation is at low dose and up-titrated.
Show evidence (1 reference)
"By decreasing heart rate, myocardial contractility and afterload, beta-adrenoceptor antagonists reduce myocardial workload and oxygen consumption at rest as well as during periods of exertion or stress."
States this node directly, and names the three upstream contributions the module models.
Beta-Blocker-Induced Bronchospasm
consequence
Clinically manifest airway narrowing attributable to beta-2 blockade. The claim is deliberately scoped: the hazard is established for non-selective blockade in asthma, while the pharmacovigilance and observational record does not show cardioselective beta-1 blockers causing asthma death or increased exacerbations. The node therefore asserts a mechanism with a selectivity precondition, not a class effect, and a conforming entry should say which agent it means.
Show evidence (3 references)
"blocking airway β2-receptors can cause severe and sometimes fatal bronchoconstriction in people with asthma"
States the adverse consequence and attributes it to beta-2 blockade specifically.
"Observational data suggest that cardioselective β1-blocker use is not associated with increased asthma exacerbations."
Bounds the node to beta-2 blockade: the same review finds no excess exacerbations with beta-1-selective agents, which supports the selectivity precondition rather than a class effect.
"Beta-adrenoceptor antagonists must be used cautiously in patients with diabetes mellitus, peripheral vascular disease, heart failure, and asthma or other obstructive airway diseases."
Records the clinical caution that follows from this arm.
Cardioselective Beta-1 Blockade
Platform:
Small molecule
Beta-1-selective antagonists, the agents used for rate control, angina and guideline-directed heart failure therapy. Selectivity is relative and falls away at high dose, which is what links this treatment to the airway arm.
Non-Selective Beta Blockade
Platform:
Small molecule
Antagonists with comparable affinity at ADRB1 and ADRB2. Used where the beta-2 action is wanted or tolerable and avoided where it is not. Several of those uses - migraine prophylaxis, portal hypertension, thyrotoxicosis - are established clinically without the step of this module that delivers them being established, so naming them here is not an offer of a conformance target; see the scope notes.
Beta Blockade with Additional Pharmacology
Platform:
Small molecule
Agents whose benefit is not exhausted by receptor blockade: carvedilol also blocks alpha-1 receptors and directly suppresses spontaneous sarcoplasmic reticulum calcium release. Its anti-arrhythmic action is modelled in `cardiac_camp_pka_calcium_handling`, not here.
Evidence: 1